The invention provides a method for validating the functioning of an apparatus with a static mixing device for mixing two liquid streams for producing nanoparticles. The static mixing device may be a jet impingement reactor. The method is based on the use of PLA, PLG or PLGA for producing polymeric nanoparticles with highly reproducible particle sizes. The invention further provides kits and liquid compositions for carrying out the method.

Provided is an aqueous solution as a continuous phase, the aqueous solution comprising: a first plurality of polymers; and a first plurality of active ingredients; and one or more nanoparticles, as a dispersed phase, the one or more nanoparticles comprising: a first plurality of carrier solvents; and a second plurality of active ingredients, wherein: the second plurality of active ingredients have at least 5 times higher absorption in-vivo when located inside the one or more nanoparticles compared to when administered in an aqueous solution.

The present disclosure generally relates to compositions and method for delivery, e.g., sustained delivery of active agents, and their use for the treatment of diseases or disorders.

Provided herein is chitosan dually derivatized with arginine and gluconic acid; and methods of making and using the same, e.g., for gene delivery in vivo.

A method for making xanthan gum copolymer nanomicelles comprising: 1) degrading xanthan gum in aqueous solution to obtain degraded xanthan gum; 2) preparing xanthan gum bromide from the degraded xanthan gum; 3) preparing xanthan gum copolymer from the xanthan gum bromide and 4) making the gum copolymer nanomicelles from the xanthan gum copolymer. The xanthan gum copolymer nanomicelles have good morphological regularity, good biocompatibility and stable performance as an anticancer drug carriers.

Aspects of the disclosure relate to nanoparticle formulations and methods for generating nanoparticles. Embodiments include nanoparticles comprising an amphiphile and a polymer co-assembly agent. In some cases, polymers for use in therapeutic delivery are described. In some embodiments, the disclosed methods and compositions involve TLR agonists and formulations thereof capable of activating an immune response. Certain aspects relate to nanoparticles comprising linked TLR agonists for use in immunotherapy.

Systems and methods for localized drug delivery via undulating drug coated balloons (DCB), in particular using functionalized nanoparticles as a drug delivery medium in combination with an undulating balloon, are disclosed. In various disclosed embodiments, a nanoparticle matrix is adhered to in an external substrate-surface, such as the balloon surface, and is activated for release once at the treatment site. Activation for release may be enhanced through the use of an undulating balloon system including methodologies for precise control of timing, waveform and extent of undulations.

A method of treatment or prevention of HIV and other viral infection comprising the administration of a biopolymer-based hydrogel nanoparticles and/or microparticles. In preferred embodiments, the particles comprise chitosan, hydroxyethyl cellulose (HEC), and linseed oil polyol. These biopolymer-based hydrogel nanoparticles and/or microparticles are antiviral agents that can be employed alone or in combination with other drugs for treatment of the viral infection. Further, the pre-treatment with the particles is highly effective at inhibiting viruses. Therefore, this antiviral biopolymer-based hydrogel nanoparticles and/or microparticles may also be employed as a prophylactic.

The present invention relates to a method for producing an andrographolide carrier system, comprising: (i) preparing a dispersed phase by dissolving andrographolide in ethanol solvent; (ii) preparing an inner encapsulating carrier layer; (iii) forming a protective encapsulating layer of the active agent; (iv) forming bonds to attach mucoadhesion enhancers onto the surface structure of the encapsulating layer, and then bringing the mixture to room temperature, slowly adding hydroxypropyl methylcellulose HPMC; (v) heating until the temperature reaches 50° C., adding Polysorbate 80 and PEG-40 hydrogenated castor oil to the mixture, with further stirring under vacuum; and (vi) filtering the product by injection through a nanofilter system.

A system for delivery of a therapeutic agent to a site in mucosal tissue is provided. The system includes a porous, mucoadhesive polymeric matrix having a first and a second opposed surfaces. The matrix is formed by a composition including chitosan. The composition may also include any or all of a hydration promotor, a microparticle adhesion inhibitor, and a microparticle aggregation inhibitor. A plurality of microparticles having an average diameter between 500 nm and 2000 nm are embedded within the matrix. The microparticles contain a therapeutic agent and have a coating around the therapeutic agent. The first surface of the matrix is configured to be attached to the site in the mucosal tissue and the matrix is configured to provide controlled release of the microparticles through the first surface. The coating of the microparticles includes chitosan so as to provide controlled release of the agent from the microparticles.